​
​

Adaptimmune Therapeutics Ownership | Who Owns Adaptimmune Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Adaptimmune Therapeutics Ownership Summary

Adaptimmune Therapeutics is owned by 63.63% institutional investors, 0.38% insiders, and 36.00% retail investors. Matrix capital management company, lp is the largest institutional shareholder, holding 16.11% of ADAP shares. Edinburgh Worldwide Ord is the top mutual fund, with 2.63% of its assets in Adaptimmune Therapeutics shares.

ADAP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockAdaptimmune Therapeutics63.63%0.38%36.00%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Matrix capital management company, lp38.97M16.11%$38.00M
Ecor1 capital27.40M11.33%$26.72M
Nea management company17.08M7.06%$16.65M
Baillie gifford15.15M6.26%$14.77M
Long focus capital management12.35M5.10%$12.04M
Pfm health sciences, lp10.52M4.35%$10.26M
Mpm asset management5.56M2.30%$5.42M
Bioimpact capital5.10M2.11%$4.97M
Bank of america corp /de/4.65M1.92%$4.53M
Rock springs capital management lp2.43M1.00%$2.36M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mpm asset management5.56M2.97%$5.42M
Nea management company17.08M1.25%$16.65M
Ecor1 capital27.40M0.82%$26.72M
Bioimpact capital5.10M0.77%$4.97M
Pfm health sciences, lp10.52M0.51%$10.26M
Long focus capital management12.35M0.46%$12.04M
Matrix capital management company, lp38.97M0.29%$38.00M
Key client fiduciary advisors263.99K0.13%$257.36K
Dafna capital management341.06K0.08%$332.50K
Rock springs capital management lp2.43M0.07%$2.36M

Top Buyers

HolderShares% AssetsChange
Long focus capital management12.35M0.46%1.66M
Renaissance1.79M0.00%394.57K
Jpmorgan chase1.04M0.00%122.21K
Pfm health sciences, lp10.52M0.51%97.10K
Lpl financial198.86K0.00%90.00K

Top Sellers

HolderShares% AssetsChange
Baker bros. advisors lp---2.34M
Tang capital management---1.74M
Baillie gifford15.15M0.01%-722.67K
Cubist systematic strategies---675.88K
Acuitas investments---541.20K

New Positions

HolderShares% AssetsChangeValue
Invesco34.74K-34.74K$33.87K
Susquehanna group, llp11.70K-11.70K$11.35K
Ifp advisors3.02K0.00%3.02K$2.95K
Parallel advisors250.00-250.00$244.00

Sold Out

HolderChange
National bank of canada /fi/-10.00
Royal bank of canada-700.00
Signaturefd-2.04K
Wetzel investment advisors-6.00K
Raymond james & associates-10.22K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202480-3.61%153,896,694-5.05%631.25%23-32.35%22-
Mar 31, 2024839.21%162,089,97112.87%710.64%3421.43%22-12.00%
Dec 31, 202376-1.30%143,609,879-3.14%1051.64%2821.74%254.17%
Sep 30, 202377-11.49%148,269,5572.49%801.05%23-59.65%24118.18%
Jun 30, 20238731.82%144,662,60624.75%871.78%57137.50%11-35.29%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Edinburgh Worldwide Ord6.72M2.63%358.03K
Baillie Gifford Global Discovery A Acc6.07M2.37%-11.06K
Baillie Gifford WW Discovery B USD Acc1.59M0.62%-16.27K
JPM Thematics Genetic Thrps C2 Acc USD939.25K0.37%-46.80K
Galileo - Biotech Innovation Fund S USD752.46K0.29%-
Mercer Global Small Cap Equity M-5£484.78K0.19%84.40K
Mercer Global Small Cap Equity M-3£484.78K0.19%84.40K
SPDR® Portfolio Developed Wld ex-US ETF246.31K0.10%-
A4Investments SICAV SIF ACCI IlanaA2EURH221.29K0.09%-
Fidelity Enhanced Small Cap ETF161.54K0.06%-1.13K

Recent Insider Transactions

DateNameRoleActivityValue
Jun 18, 2024Piccina Cintia Chief Commercial OfficerSell$22.81K
Jan 16, 2024Rawcliffe Adrian Chief Executive OfficerSell$7.35K
Jan 17, 2024Rawcliffe Adrian Chief Executive OfficerSell$20.24K
Jan 17, 2024Norry Elliot Chief Medical OfficerSell$3.57K
Jan 17, 2024Norry Elliot Chief Medical OfficerSell$8.73K

Insider Transactions Trends

DateBuySell
2024 Q3--
2024 Q2-1
2024 Q1-19
2023 Q4--
2023 Q3-3

ADAP Ownership FAQ

Who Owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics shareholders are primarily institutional investors at 63.63%, followed by 0.38% insiders and 35.99% retail investors. The average institutional ownership in Adaptimmune Therapeutics's industry, Biotech Stocks , is 44.97%, which Adaptimmune Therapeutics exceeds.

Who owns the most shares of Adaptimmune Therapeutics?

Adaptimmune Therapeutics’s largest shareholders are Matrix capital management company, lp (38.97M shares, 16.11%), Ecor1 capital (27.4M shares, 11.33%), and Nea management company (17.08M shares, 7.06%). Together, they hold 34.50% of Adaptimmune Therapeutics’s total shares outstanding.

Does Blackrock own Adaptimmune Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Adaptimmune Therapeutics.

Who is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.97% of its assets in 5.56M Adaptimmune Therapeutics shares, valued at 5.42M$.

Who is the top mutual fund holder of Adaptimmune Therapeutics shares?

Edinburgh Worldwide Ord is the top mutual fund holder of Adaptimmune Therapeutics shares, with 2.63% of its total shares outstanding invested in 6.72M Adaptimmune Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools